A recent study showed that nivolumab, the first programmed cell death-1 (PD-1) inhibitor, plus chemotherapy had superior OS and PFS with tolerable toxicity profile in patients with previously untreated advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma (18). The gene discussed is PDCD1; the disease is esophageal adenocarcinoma.